The performance of 11C-Methionine PET in the differential diagnosis of glioma recurrence

Weilin Xu; Liansheng Gao; Anwen Shao; Jingwei Zheng; Jianmin Zhang

doi:10.18632/oncotarget.19024

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

The performance of 11C-Methionine PET in the differential diagnosis of glioma recurrence

Weilin Xu, Liansheng Gao, Anwen Shao, Jingwei Zheng and Jianmin Zhang _

PDF | HTML | How to cite

Oncotarget. 2017; 8:91030-91039. https://doi.org/10.18632/oncotarget.19024

Metrics: PDF 2045 views | HTML 2521 views | ?

Abstract

Weilin Xu1,*, Liansheng Gao1,*, Anwen Shao1,*, Jingwei Zheng1 and Jianmin Zhang1,2,3

1Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

2Brain Research Institute, Zhejiang University, Hangzhou, Zhejiang, China

3Collaborative Innovation Center for Brain Science, Zhejiang University, Hangzhou, Zhejiang, China

*These authors have contributed equally to this work as co-first authors

Correspondence to:

Jianmin Zhang, email: [email protected]

Keywords: methionine, PET, glioma, recurrence, meta-analysis

Received: April 28, 2017 Accepted: June 20, 2017 Published: July 05, 2017

ABSTRACT

Despite the advancement of neuroimaging techniques, it often remains a diagnostic challenge to distinguish recurrent glioma from lesions representing treatment effect. Preliminary reports suggest that 11C-methionine Positron emission tomography (PET) can assist in diagnosing true glioma recurrence. We present here a meta-analysis to assess the accuracy of 11C-methionine PET in identifying recurrent glioma in patients who had undergone prior therapy. A comprehensive search of the PubMed, Embase and Chinese Biomedical (CBM) databases yielded 23 eligible articles comprising 29 studies listed prior to November 20, 2016, representing 891 patients. In this report, we assess the methodological quality of each article individually and perform a meta-analysis to obtain the summary diagnostic accuracy of 11C-methionine PET in correctly identifying recurrent glioma. The pooled sensitivity and specificity are 0.88 (95% CI: 0.85, 0.91) and 0.85 (95% CI: 0.80, 0.89), respectively, with an area under the curve (AUC) for the summary receiver-operating characteristic curve (SROC) of 0.9352. We conclude that 11C-methionine PET has excellent diagnostic performance for differentiating glioma recurrence from treatment effect.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19024

Publication Alerts

Research Papers:

The performance of 11C-Methionine PET in the differential diagnosis of glioma recurrence

Abstract